■更年期与生物衰老有关,激素治疗(HT)与绝经后妇女的健康结局相关。
■评估绝经后妇女使用HT与实际年龄和生物学年龄差异之间的关联,以及社会经济地位(SES)的潜在改变作用。
■这种以人口为基础的,回顾性队列研究纳入了在英国生物银行注册的绝经后女性.从2006年3月至2010年10月进行了一项关于HT使用和生物衰老生物标志物的基线调查。数据分析于2023年12月进行。
■有关HT使用的信息,开始HT的年龄,和HT持续时间通过触摸屏问卷收集。SES是通过教育评估的,家庭收入,职业,和汤森剥夺指数.
■使用验证的表型年龄评估生物老化差异,这是使用实际年龄和基线测量的9种生物标志物计算的。还评估了所有原因和特定原因的死亡率。
■在117763名绝经后妇女中(平均[SD]年龄,60.2[5.4]年),47461(40.3%)曾经使用过HT。平均表型年龄为52.1(7.9)岁。与从未使用HT相比,使用HT与较小的生物衰老差异有关(β,-0.17年;95%CI,-0.23至-0.10年)。这种较小的老化差异在55岁或以上开始HT的人群中更为明显(β,-0.32年;95%CI,-0.48至-0.15年),并且在使用HT4至8年的人中(β,-0.25年;95%CI,-0.35至-0.15年)。在SES较低的女性中,HT与较小的衰老差异之间的关联更为明显。在教育中观察到显著的相互作用(高等教育:β,-0.08年[95%CI,-0.17至0.01];其他教育:β,-0.23[95%CI,-0.32至-0.14]年;交互作用的P=.02)。表型老化差异介导了12.7%(95%CI,6.3%至23.9%)的HT与全因死亡率和特定原因死亡率之间的关联。
■在这项研究中,历史上使用HT的绝经后妇女在生物学上比没有接受HT的妇女年轻,在SES较低的人群中观察到更明显的关联。生物衰老差异介导了HT与死亡率降低之间的关联。在绝经后妇女中促进HT对健康衰老可能很重要。
UNASSIGNED: Menopause is associated with biological aging, and hormone therapy (HT) is associated with health outcomes in postmenopausal women.
UNASSIGNED: To evaluate the association between HT use and discrepancies between chronological and biological age in postmenopausal women as well as the potential modifying role of socioeconomic status (SES).
UNASSIGNED: This population-based, retrospective cohort study included postmenopausal women registered in the UK Biobank. A baseline survey on HT use and biological aging biomarkers was conducted from March 2006 to October 2010. Data analyses were conducted in December 2023.
UNASSIGNED: Information regarding HT use, the age at starting HT, and HT duration was collected via a touchscreen questionnaire. SES was evaluated by education, family income, occupation, and the Townsend Deprivation Index.
UNASSIGNED: Biological aging discrepancy was evaluated using validated phenotypic age, which was calculated using chronological age and 9 biomarkers measured at baseline. All-cause and cause-specific mortality were also assessed.
UNASSIGNED: Among the 117 763 postmenopausal women (mean [SD] age, 60.2 [5.4] years), 47 461 (40.3%) ever used HT. The mean phenotypic age was 52.1 (7.9) years. Ever use of HT was associated with a smaller biological aging discrepancy than never use of HT (β, -0.17 years; 95% CI, -0.23 to -0.10 years). This smaller aging discrepancy was more evident in those who started HT at age 55 years or older (β, -0.32 years; 95% CI, -0.48 to -0.15 years) and in those who used HT for 4 to 8 years (β, -0.25 years; 95% CI, -0.35 to -0.15 years). The association between HT and a smaller aging discrepancy was more evident in women with low SES, with a significant interaction observed for education (higher education: β, -0.08 years [95% CI, -0.17 to 0.01]; other education: β, -0.23 [95% CI, -0.32 to -0.14] years; P for interaction = .02). Phenotypic aging discrepancy mediated 12.7% (95% CI, 6.3% to 23.9%) of the association between HT and all-cause mortality and cause-specific mortality.
UNASSIGNED: In this study, postmenopausal women with historical HT use were biologically younger than those not receiving HT, with a more evident association observed in those with low SES. The biological aging discrepancy mediated the association between HT and decreased mortality. Promoting HT in postmenopausal women could be important for healthy aging.